Transcriptional Heterogeneity of Cardiac Remodeling Between Type 1 and Type 2 Diabetes

Feng Liang1, Shaohua Li2, Guo Zhou1

  • 1Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.

Biomedicines
|May 4, 2026
PubMed

Insights

Type 1 and type 2 diabetes share common cardiac pathway alterations, despite differences in gene expression. Targeting these shared pathways offers potential for treating diabetic cardiomyopathy.

Area of Science:

  • Cardiovascular Research
  • Metabolic Disorders
  • Molecular Biology

Background:

  • Diabetes mellitus, encompassing type 1 (T1D) and type 2 (T2D), significantly elevates heart failure risk.
  • Existing research lacks clarity on distinct pathway alterations in T1D versus T2D-induced cardiac complications.
  • Understanding cardiac remodeling heterogeneity is crucial for clinical management of diabetic cardiovascular events.

Purpose of the Study:

  • To investigate and compare gene and pathway alterations in cardiac remodeling between T1D and T2D models.
  • To identify cell-specific pathway differences and commonalities in diabetic cardiomyopathy.
  • To provide insights for targeted therapeutic strategies against diabetic cardiomyopathy.

Main Methods:

  • Establishment of T1D and T2D mouse models for comprehensive cardiac tissue analysis.
  • RNA sequencing and differential expression analysis to identify molecular changes.
  • Single-cell RNA sequencing (scRNA-seq) to compare endothelial cells, macrophages, and fibroblasts in T1D and T2D hearts.
  • Functional enrichment analysis to determine pathway heterogeneity and commonalities.

Main Results:

  • T1D and T2D models exhibited more conserved pathway changes than shared gene alterations.
  • Endothelial cells, macrophages, and fibroblasts were identified as key cell types in diabetic cardiac phenotype.
  • Specific pathways enriched in T1D (e.g., inflammation, fatty acid metabolism) and T2D (e.g., energy metabolism) were observed.
  • Common pathways across cell types involved innate immunity and cardiac morphogenesis, with pathways showing higher consistency than genes.

Conclusions:

  • Cardiac pathologies in T1D and T2D demonstrate greater consistency in pathway changes compared to gene-level alterations.
  • Targeting common pathways identified in this study may offer a promising therapeutic avenue for diabetic cardiomyopathy.
  • This research highlights the value of pathway-level analysis in understanding and treating complex diseases like diabetic cardiomyopathy.

Related Concept Videos

Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
17
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
28
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
75
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790